2. Academic Validation
  3. Self-renewal as a therapeutic target in human colorectal cancer

Self-renewal as a therapeutic target in human colorectal cancer

  • Nat Med. 2014 Jan;20(1):29-36. doi: 10.1038/nm.3418.
Antonija Kreso 1,  Peter van Galen 2,  Nicholas M Pedley 3,  Evelyne Lima-Fernandes 4,  Catherine Frelin 5,  Thomas Davis 6,  Liangxian Cao 6,  Ramil Baiazitov 6,  Wu Du 6,  Nadiya Sydorenko 6,  Young-Choon Moon 6,  Lianne Gibson 3,  Yadong Wang 3,  Cherry Leung 3,  Norman N Iscove 7,  Cheryl H Arrowsmith 8,  Eva Szentgyorgyi 9,  Steven Gallinger 10,  John E Dick 11,  Catherine A O'Brien 12
Affiliations

Affiliations

  • 1 1] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. [2] Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • 2 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • 3 1] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. [2] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • 4 Structural Genomics Consortium, Toronto, Ontario, Canada.
  • 5 1] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. [2] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • 6 PTC Therapeutics, South Plainfield, New Jersey, USA.
  • 7 1] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. [2] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. [3] Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • 8 1] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. [2] Structural Genomics Consortium, Toronto, Ontario, Canada. [3] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • 9 Department of Pathology, Toronto General Hospital, Toronto, Ontario, Canada.
  • 10 1] Department of Surgery, Toronto General Hospital, Toronto, Ontario, Canada. [2] Fred Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • 11 1] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. [2] Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada. [3].
  • 12 1] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. [2] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. [3] Department of Surgery, Toronto General Hospital, Toronto, Ontario, Canada. [4].
PMID: 24292392 DOI: 10.1038/nm.3418
Abstract

Tumor recurrence following treatment remains a major clinical challenge. Evidence from xenograft models and human trials indicates selective enrichment of cancer-initiating cells (CICs) in tumors that survive therapy. Together with recent reports showing that CIC gene signatures influence patient survival, these studies predict that targeting self-renewal, the key 'stemness' property unique to CICs, may represent a new paradigm in Cancer therapy. Here we demonstrate that tumor formation and, more specifically, human colorectal CIC function are dependent on the canonical self-renewal regulator BMI-1. Downregulation of BMI-1 inhibits the ability of colorectal CICs to self-renew, resulting in the abrogation of their tumorigenic potential. Treatment of primary colorectal Cancer xenografts with a small-molecule BMI-1 inhibitor resulted in colorectal CIC loss with long-term and irreversible impairment of tumor growth. Targeting the BMI-1-related self-renewal machinery provides the basis for a new therapeutic approach in the treatment of colorectal Cancer.

Figures
Products